{"url_path":"/sec/allr/8-k/2026-06-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Matters.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","accession_number":"0001213900-26-070382","cik":"0001860657","ticker":"ALLR","issuer_name":"Allarity Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","primary_entity_key":"0001860657","primary_entity_name":"Allarity Therapeutics, Inc."},"word_count":55,"has_tables":true,"body_markdown":"**Item 8.01 Other Matters.**\n\n \n\nOn June 22, 2026, Allarity Therapeutics, Inc.\n(the “Company”) announced its presentation of a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026,\nwhich was held June 17–19, 2026, in Copenhagen, Denmark. A copy of the Company’s press release is attached hereto as Exhibit\n99.1 and is incorporated herein by reference."}